RxStrategies, Inc.

Happy New Year from RxStrategies

May your 2023 be filled with health, joy and success! Thank you for making RxStrategies your trusted #340B solution. Happy New Year!

Read More...

Clinical Insights: January 4, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Briumvi™ (ublituximab-xiiy) Injection – New Drug Approval – December 28, 2022 – TG Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Briumvi™ (ublituximab-xiiy), for the…

Read More...

Clinical Insights: December 28, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sunlenca® (lenacapavir) – New Drug Approval – December 22, 2022 – Gilead Sciences, Inc. announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by…

Read More...

Clinical Insights: December 21, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Adstiladrin® (nadofaragene firadenovec-vncg) – New Drug Approval ­– December 16, 2022 – The U.S. Food and Drug Administration approved Adstiladrin® (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells)…

Read More...

Holiday Wishes from RxStrategies

This holiday season, we would like to take a moment to thank our customers and partners for their trust. We are honored to support your pharmacy operations with next-generation solutions for mixed-used #340B inventory management and contract pharmacy administration. Thank you for all you do to support those in your care. On behalf of our…

Read More...

Introducing: The 340B Insider Podcast

We are excited to announce the launch of our new educational podcast, the 340B Insider Podcast. Listen in as we detail more about the focus of the upcoming episodes that will include leading 340B, technology and pharmacy professionals who provide clinical insights and the latest information to help support your 340B program. Check out our…

Read More...

Clinical Insights: December 14th, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 09, 2022 Methylphenidate Hydrochloride Extended Release Tablets (Discontinuation) December 08, 2022 Etodolac Tablets (Discontinuation) Promethazine Tablets…

Read More...

Clinical Insights: December 7, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Rezlidhia™ (olutasidenib) Capsules – New Drug Approval ­– December 1, 2022 – The Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia™) capsules for adult patients with relapsed or refractory…

Read More...

Clinical Insights: November 30, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Hemgenix™ (etranacogene dezaparvovec-drlb) Suspension for Intravenous Infusion – New Drug Approval – November 22, 2022 – The U.S. Food and Drug Administration approved Hemgenix™ (etranacogene dezaparvovec), an adeno-associated virus…

Read More...

Clinical Insights: November 23, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Tzield™ (teplizumab-mzwv) – New Drug Approval – November 18, 2022 – The U.S. Food and Drug Administration approved Tzield™ (teplizumab-mzwv) injection to delay the onset of stage 3 type…

Read More...

Clinical Insights: November 16, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Elahere™ (mirvetuximab soravtansine-gynx) Injection – New Drug Approval – November 14, 2022 – The Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere™, ImmunoGen, Inc.) for adult…

Read More...

Clinical Insights: November 9, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage November 08, 2022 Glucagon Injection (Discontinuation) Hydrochlorothiazide and Spironolactone (Aldactazide) Tablets (Discontinuation) November 02, 2022 Butenafine Hydrochloride…

Read More...